MDxHealth SA · NASDAQ:MDXH

MDxHealth SA — Investor Presentation (October 2020)

22 slides from MDxHealth SA's investor presentation, October 2020

  1. Slide 1: Corporate Presentation October 2020

    CORPORATE PRESENTATION October 2020

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements & estimates made by the management of the Company with respect to the anticipated future performance of MDxHealth & the market in which it operates. Such statements & estimates are based on various assumptions & assessme

  3. Slide 3: Delivering life changing genomic technologies for early prostate cancer detection

    Delivering life changing genomic technologies to improve the early detection of prostate cancer Providing clinically actionable information to improve patient outcomes Improving patient care while reducing medical costs Providing a value-based experience for patients, clinicians and providers Ticker

  4. Slide 4: Experienced Leadership Team

    Experienced Leadership Team Proven track record of success Miriam Reyes Joseph Sollee Michael K. McGarrity Ron Kalfus John Bellano Executive Vice President Executive Vice President Chief Executive Officer Chief Financial Officer Chief Commercial Officer Laboratory Operations Corp. Dev. & General Cou

  5. Slide 5: Investment Highlights

    Investment Highlights Novel tests are based on proprietary genetic, epigenetic Two clinically validated, commercially established, (methylation) and other molecular technologies to assist revenue generating diagnostic tests for prostate physicians with the diagnosis of urologic cancers cancer Curren

  6. Slide 6: Current Challenges with Diagnosing Prostate Cancer in the U.S.

    Current Challenges with Diagnosing Prostate Cancer in the U.S. 2020 ACS Surveillance Research #1 Most Common Cancer in U.S. Men 3 million elevated PSA results annually(1-2) 191,930 of biopsies do not reveal 116,300 cancer and may lead to 78,300 62,100 60,190 60% increased complications and hospitali

  7. Slide 7: U.S. Annual Market Opportunity

    U.S. Annual Market Opportunity Prostate Cancer is the Most Common Cancer in American Men Who needs Who needs a Who needs a biopsy? repeat biopsy? treatment? 25M 500K 200K 3M PSA tests Prostate biopsies New prostate Living with prostate 33,350 performed performed cancer cases cancer Estimated Deaths

  8. Slide 8: MDxHealth's Prostate Cancer Menu

    MDxHealth’s Prostate Cancer Menu Clinical Pathway for Diagnosing Aggressive Prostate Cancer Improving the decision for Improving the decision for initial prostate biopsy repeat prostate biopsy Cancer Biopsy / Biopsy / Positive Positive Imaging Imaging Routine Screening No Cancer Negative Negative ©2

  9. Slide 9: Improved Patient Selection Prior to Prostate Biopsy

    Improved Patient Selection Prior to Prostate Biopsy The most highly predictive test to help identify men at low risk for aggressive prostate cancer At risk for aggressive cancer? Positive Biopsy Routinely Negative Monitor Abnormal PSA/DRE 95% NPV Binary Actionable Results for patient and HCP • Non-i

  10. Slide 10: Robust Clinical Evidence

    : Robust Clinical Evidence 12 published studies on genes and technology (> 3,500 patients) Clinical Utility Clinical Validity Analytical Validity Health Economics Pivotal Clinical Studies Hessels et al., Analytical Validation Translational Medicine Communications 2017 Govers et al., >$500M In Saving

  11. Slide 11: The only epigenetic test to identify men at risk for aggressive prostate cancer

    The only epigenetic test to identify men at risk for aggressive prostate cancer 12-core needle biopsy could miss the mark Positive Biopsy Core Cancer Rebiopsy Positive Field Effect MRI Cancer Prostate Avoid Rebiopsy Biopsy Core Urethra Prostate Negative /MRI Needles Negative biopsy 96% NPV3 • Non-in

  12. Slide 12: Robust Clinical Evidence

    : Robust Clinical Evidence Over 55 published studies on genes and technology (> 5,500 patients) Clinical Utility Clinical Validity Analytical Validity Health Economics Pivotal Clinical Studies Van Neste et al., Analytical Validation BMC Urology 2013 Aubry et al., $500K In Savings To Health Care Syst

  13. Slide 13: Clinical Guideline Inclusion

    Clinical Guideline Inclusion 2012 2016 2018 2018 2020 PSA screening ConfirmMDx is PSA testing resumes MDxHealth tests SelectMDx is included reduced/eliminated due included in the NCCN due to US Preventive included in European in the NCCN to US Preventive Early Detection of Services Task Force Associ

  14. Slide 14: Expanding R&D Into the Prostate Cancer Diagnostic Pathway

    Expanding R&D Into the Prostate Cancer Diagnostic Pathway SCREENING PATIENT SELECTION DIAGNOSIS ACTIVE SURVEILLANCE (AS) Intervention Biopsy Negative Biopsy/Imaging Active Surveillance AS monitoring Biopsy decision Prostate Cancer Initial Low-Grade AS-MDx Monitor-MDx Intervention PSA Screening Test

  15. Slide 15: AS-MDx: Diagnostic Patient Disposition for Active Surveillance

    AS-MDx: Diagnostic Patient Disposition for Active Surveillance Not all men diagnosed with Positive Intervention localized prostate cancer may benefit from immediate intervention. These tumors can AS-MDx be slow growing and non-life Active threatening Negative Surveillance Low-grade prostate cancer A

  16. Slide 16: Monitor-MDx: Validates Continued Monitoring Under Active Surveillance

    Monitor-MDx: Validates Continued Monitoring Under Active Surveillance Positive Intervention Patients under active surveillance are currently monitored by invasive and Monitor-MDx costly prostate biopsy procedures Continued Active Negative • Monitor-MDx provides non-invasive Surveillance Under Active

  17. Slide 17: Proven Fundamental Foundation Driving Value Creation

    Proven Fundamental Foundation Driving Value Creation Strong Commercial Focus Proven Reimbursement Robust and Reliable Technology and Presence Strategy Proprietary IP portfolio capable of advancing our diagnostic pathway in Leveraging direct sales force in U.S. ConfirmMDx covered by Medicare and pros

  18. Slide 18: MDxHealth Adoption and Reorder Rates Accelerating

    MDxHealth Adoption and Reorder Rates Accelerating • Considerable value in the current MDxHealth menu Diagnostic S-curve adoption model and customer base will drive significant revenue growth, as adoption progresses up the S-curve • By driving adoption through our high-quality physician base with the

  19. Slide 19: Guideline Inclusion and Managed Care Contracts Payer Adoption

    MDxHealth Guideline Inclusion and Managed Care Contracts 120 Payer Adoption SelectMDx 100 in NCCN (2H20) Summary ConfirmMDx and SelectMDx in EAU (1H18) 80 ConfirmMDx in NCCN 60 (1H16) ü 2016 NCCN Guidelines inclusion ü 96 payer contracts – 1H20 Launch 40 ConfirmMDx LCD (Medicare coverage) (2H14) Lau

  20. Slide 20: Robust and Reliable Technology

    Robust and Reliable Technology • MDxHealth continues to be at the forefront of researching and understanding the link between cancer and methylation, and how this link can be translated into meaningful molecular diagnostic tests. • MDxHealth utilizes proprietary molecular technologies to advance can

  21. Slide 21: Thank You

    Thank You Global Operations General Inquiries [email protected] Investor Relations Contact LifeSci Advisors, LLC (IR & PR) U.S. Headquarters & Laboratory Global Headquarters R&D & Laboratory US +1 949 271 9223 15279 Alton Parkway, Ste 100 CAP Business Center Novio Tech Campus Transistorweg 5 Irvine

  22. Slide 22: Presentation References

    Presentation References SUMMARY REFERENCE CITATIONS Slide 6 – Current challenges with diagnosing prostate cancer in U.S. 1. NIH 8/20/2019 Website: https://seer.cancer.gov/statfacts/html/common.html. 2. MDxHealth management estimates 3. Moyer VA, U.S. Preventive Services Task Force. Screening for pro

MDxHealth — Investor Presentation (October 2020) on 6ix